Leveraging Strategic Collaboration for Early Stage Innovation
Chief Operating Officer, Johnson & Johnson，
Arjun “JJ” Desai is Chief Operating Officer of JLABS and the Center for Device Innovation at the Texas Medical Center (CDI @ TMC). JJ is responsible for delivering on the goals and objectives across all JLABS sites, in addition to CDI @ TMC.
Prior to joining the Johnson & Johnson Innovation, JLABS family, JJ served as Chief Medical Officer at Avinger, Inc., a medical device company that develops Lumivascular image guided therapies, which combines real-time intravascular imaging with therapeutic devices to address cardiovascular diseases.
JJ completed his advanced anesthesia residency at Stanford University, where he served as chief resident his final year, and he remains on faculty as a Clinical Instructor in the Department of Anesthesia. JJ currently lectures at both Stanford Healthcare and Stanford Biodesign.
Prior to clinical training, JJ served as a fellow in the United States House Policy Committee, advising members of Congress on early Medicare legislation, which ultimately shaped Medicaid and outreach programs. Additionally, he represented the United States State Department and Rotary International as an Ambassador of Goodwill to Singapore where he led vaccine prophylaxis campaigns and taught in the department of health economics at the National University of Singapore. In addition to his role as a Stanford physician, he holds an M.D. from the University of Miami, Miller School of Medicine and a B.A. in Economics from the University of Oklahoma.
Efficient Asymmetric Synthesis of Enantio-Enriched Compounds
Professor Masahiro Terada was born in Tokyo in 1964. He was graduated from Department of Applied Chemistry, Tokyo Institute of Technology in 1986 and completed his Ph.D. degree in 1993 from Tokyo Institute of Technology under the direction of Professor Koichi Mikami. During his Ph.D. study, he was appointed as an assistant professor in Professor Mikami’s Laboratory at Tokyo Institute of Technology (1989-2001). He worked as a postdoctoral fellow with Professor M. D. Shair at Harvard University in 1999-2000 and moved to Tohoku University as an associate professor in 2001. He has been a Professor of Chemistry at the Graduate School of Science, Tohoku University since 2006. He is the recipient of: The Incentive Award in Synthetic Organic Chemistry, Japan (2003), The Chemical Society of Japan Award for Creative Work (2008) Mukaiyama Award (2010), Daiichi-Sankyo Award for Medicinal Organic Chemistry (2011), The Nagoya Silver Medal (2012), Molecular Chirality Award 2015 (2015), and Synthetic Organic Chemistry Award, Japan (2017). His current research interests are the development of new and useful synthetic methodologies based on the design of novel chiral Br?nsted acid and base catalysts as well as the utilization of transition metal catalysts.
Safe Technologies for Cell Culture and Therapies
Goodwin Endowed Chair Professor, Medical College of Virginia/ Virginia Commonwealth University
Professor Xuejun Wen is engaged in biomaterials, medical devices, nanotechnology, new drug development and delivery, 3D printing and bio-fabrication, biosensor, stem cell technology, tissue engineering and regenerative medicine research and technical applications, including synthetic biomaterials, synthesis of bioactive peptide based biomaterials, natural modified antibacterial biomaterials, Injectable hydrogels, 3D bioprinting, three-dimensional culture technologies with the broad applications in the areas of orthopedics, nervous system, cardiovascular system, ophthalmological, oral, dermatological and other tissue repairs, precision medicine, drug screening, gene therapy applications. He published more than 100 research papers, including high impact journals such as "Lancet", "Progress in Polymer", "Scientific Reports", "FASEB Journal", "Advanced Functional Materials", "Advanced Healthcare Materials”, "Journal of Neuroscience", "biomaterials" and so on. He was awarded the esteemed National Science Foundation CAREER award in 2008. He was ranked the first on the "2014 Highly cited Chinese scholar list" in the biomedical engineering field by the Elsevier. He continued to be in the 2015, 2016, and 2017 Highly cited scholar list. Since 2003, he developed more than 120 core platform technologies, has applied for more than 20 patents with 16 issued patents. The following 13 representative technologies are derived from his list of innovations: (1) Stem cell culture technique based on fully synthetic looped peptides, (2) Brain tissue Regeneration technology, (3) Minimally invasive regenerative technology for acute spinal cord injury; (4) Bionic intervertebral discs manufactured by 3D Printing Technology (5) Minimally invasive cartilage regeneration technology, (6) biodegradable, non-toxic, no toxic tissue adhesive technology, (7) Highly biocompatible antimicrobial technology with no bacterial resistance, (8) Antibacterial technology with plasticizing proteins, (9) 3D printed vascular grafts with natural histology and biomechanical properties, (10) Accelerated tissue maturation technology (11) Non-toxic nanoparticles for transfection and gene therapy, (12) microwell technologies for 3D cell culture and tissue formation, (13) integrin-binding peptide array technology; and so on.
President / Deputy Director of Administration, Shanghai Clinical Center,CAS / Shanghai Xuhui Central Hospital
Single Cell technique to generate full human monoclonal antibody and its application
Prof. Bing Sun is from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (in Shanghai, China) and was a chief, Lab of Molecular Immunology, He has MD and Ph.D. He has been working on Dendritic Cell maturation and T helper cell differentiation and their functions in autoimmune diseases. He has identified that Trim-30a, Dec2 and ECM1 are key molecules in controlling innate immunity and Th2 cell-mediated response (Nature Immunology 2008, 2009 and 2011). Since 2003 he has been working on viral ion channel protein, he has discovered 3a protein of SARS and P7 protein of HCV are an ion channel protein, which are important for viral life cycle and potential a drug target (PNAS 2006, Nature 2013). Currently the study is mainly to focus on the interaction of Th2 cells and ILC2 in asthma diseases. His lab developed single cell-PCR technique to generate many full-human monoclonal antibody against viral infections. He was a funding director for Shanghai Institute of Pasteur in CAS and he established a whole program (2005 to 2016) for the institute to work on pathogen, immunology and vaccine. He was as a postdoctoral fellow at NIH, USA from 1994-1999.
Brian B. Rudkin
Research Director, Stem Cell & Brain Research Institute INSERM, Univ Lyon & East China Normal University (ECNU) Shanghai
virosome-based influenza vaccine
CEO, HOPE MUCOSAL VACCINES
Born in France, Christian ROCHET received a Bachelors degree in marketing from the University of Grenoble followed by an MBA from Sherbrooke University in Canada, finishing at Harvard Business School in Boston for post-graduate studies (ITP). His first business experience was with the Gillette Group as a product manager with Braun household appliances and with Gillette – Europe, as market research manager. He subsequently accepted a position as a professor at the EM-Lyon Business school in Lyon, France. During this period, he wrote a book on industrial diversification and founded a consulting firm, advising and accompanying top managers in their diversification projects. In 2003, he accepted to become President & CEO of a biotech start-up by the name of Mymetics.
Mymetics focused on a prophylactic HIV-AIDS vaccines. Under Christian’s leadership, the company raised close to € 45 million in private funding, financing successful preclinical and human phase 1 clinical trials, which were published in high-level journals. To reinforce the company’s position while diversifying the risk, Christian conducted two strategic acquisitions. These resulted in the creation of a comprehensive product portfolio, which has enabled the company to develop four preventive vaccines.
His latest venture, "Hope Mucosal Vaccines”, S.A. (HMV), is focusing on developing the prophylactic HIV /AIDS Vaccine, under a worldwide exclusive Licencing agreement with Mymetics.
Hua Zhang got a Master diploma in Engineering and B.S. in Cellular Biology & Genetics from Peking University separately in 2010 and 1989.
From 1989 to 2001, she engaged to QC, QA and production management in pharmaceutical industry, serviced for Shanghai Institute of Biological Products, Shanghai Johnson & Johnson Co., Ltd., Sino-American Shanghai Squibb Pharmaceutical Co., Ltd. and Shanghai Abbott Pharmaceutical Co., Ltd.
In 2001, she joined in Center for Certification & Evaluation, SHFDA and became a GMP inspector. Now she is Chief Inspector and Vice General Director. She was involved in drafting “GMP Inspection Guidelines” for SFDA in 2002, as a main drafter of API part. She participated in translation of EU GMP basic requirements and annex in 2006, WHO GMP requirements in 2008. From 2006 she became one of main drafters to revise China GMP. She got Special Government Allowance of State Council in 2014 and won Model Staff of Shanghai Municipal City between 2010 and 2014. During March and July, 2015, she worked for Pre-qualification Team, World Health Organization as a rotational GMP inspector.
Chief Physician, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine
The Golden Age of Medical Informatization
Director, Division of Science and Education, Shanghai Municipal Commission of Health and Family Planning
Main Academic Association：
Consultant of evidence-based medicine center of Fudan university, vice chairman of community health alliance of Chinese medical association, standing member of the scientific research management professional committee of Chinese medical association, standing member of health technology application management experts committee of MoH, editor-in-chief of Transformation of medical and scientific research management magazine, vice editor-in-chief of Chinese Journal of Medical Science Research Management, vice editor-in-chief of The world cancer magazine, Shanghai Medical Education magazine, The world infected magazine, and editor of close to 10 of academic journals.
Professor, State Key Lab of Respiratory Disease
Dr. Chen is a Professor in Guangzhou Medical University, and a Senior Research Fellow in Guangzhou Institute of Biomedicine and Health (GIBH), where he was the founding Director General from 2004-2008. Dr. Chen received a medical degree from Shanghai Medical College in 1984. He was selected as a CUSBEA Fellow in 1984 and went to USA to pursue a Ph.D. in Indiana University School of Medicine. Dr. Chen completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School. From 1997-2001, Dr. Chen served as a Senior Research Fellow at Merck Research Laboratories, where he was the first inventor on Merck’s MRK Ad5 based AIDS vaccine that entered phase IIb clinical trial worldwide. Dr. Chen served as Vice Presidents of R&D for GlaxoSmithKline in 2009-2011 and in 2012 as Vice President at Sanofi Pasteur. Dr. Chen has over 100 publications in infectious diseases, vaccine research, cancer research, and drug discovery in journals including Nature, Nature Communications, Journal of Clinical Investigation, Cancer Research, Blood, Journal of Virology, Journal of Immunology, Vaccine., etc. He is the first inventor or co-inventor on more than 30 granted or pending US, China, and world patents.
Molecular mechanism on Interspecies transmission of influenza viruses
Yi Shi is the deputy director and a professor of CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences. He received bachelor degree from Zhejiang University in 2006 and Ph.D. degree in Biochemistry and Molecular Biology from Institute of Microbiology, Chinese Academy of Sciences in 2011. From 2011 to 2016, he worked in George Fu Gao’s lab in Institute of Microbiology as an assistant professor and then in Beijing Institutes of Life Sciences as an associate professor. He started his independent career at Institute of Microbiology, Chinese Academy of Sciences since March 2016. He also joined the Medical School, University of Chinese Academy of Sciences as a part-time professor in October 2015. Dr. Shi’s long standing interest mainly focus on the molecular mechanism of pathogen infection and regulation by the host, and the interaction between receptors and ligands during immune response. He has published more than 70 papers in leading journals such as Nature, Science, Cell, Nature Structural & Molecular Biology, Nature Communications, EMBO Journal, Journal of Virology, etc. He also received several prestigious awards such as Excellent Young Scholar from Natural Science Foundation of China (2016), the 1st VCANBIO Award for Innovations and Breakthroughs in Life Sciences and Medicine (2016), the CAS Lu Jiaxi Young Talent Award (2014), and was selected as a member of Youth Innovation Promotion Association of CAS (2015).
Prof. Shi has made remarkable contribution to interaction between infectious pathogen and the host.
a. Interspecies transmission mechanism of influenza viruses
Prof. Shi has made many contributions into how the influenza A viruses overcome host barriers. Influenza A virus uses sialic acid as the cell entry receptor, in which human and avian viruses use different configurations of sialic acid for entry, thereof requiring different amino acids in viral HA for binding. Prof. Shi characterized the HA proteins from the 1918 and 2009 pandemic H1N1 influenza viruses, and discovered that both HAs preferentially bound to the human receptor (Protein Cell, 2010; Journal of Virology, 2013). The team also revealed how a single substitution mutation Q226L and the loss of an N158-glycosylation site alter H5 receptor-binding preferences, resulting in efficient airborne transmission between ferrets (Science, 2013a; Protein Cell, 2013). Furthermore, his work showed that the 2013-H7N9 avian flu virus Anhui1 acquired the ability to bind human receptors, thus becoming prevalent, whereas non-prevalent Shanghai1 does not (Science, 2013b). In addition, Prof. Shi has been involved in the demonstration of mechanisms for “host jump” of other human-infecting AIVs, such as H6N1 (EMBO Journal, 2015), H10N8 (Nature Communications, 2015), and H13/H16 subtypes (Journal of Virology, 2012; 2013), and the non-canonical characters of bat-derived influenza-like virus HA (H17/H18) (Cell Reports, 2013; Trends in Microbiology, 2014). He and his colleagues have summarized the structural basis of receptor binding switch for influenza A viruses (Nature Reviews Microbiology, 2014).
b. Entry mechanism of EBOV
Prof. Shi solved the crystal structure of the primed GP (GPcl) of EBOV bound to its endosome-residing receptor: domain C of Niemann-Pick C1 (NPC1-C), and proposed a novel fusion triggering mechanism of enveloped viruses (Cell, 2016a). He was also involved in a subsequent collaborative study that determined cryo-EM structures of full-length NPC1 and reveals insights into cholesterol trafficking and EBOV infection (Cell, 2016b). These research findings greatly expand our understanding in virus-host membrane fusion triggering mechanism, and provide a molecular basis for the design of therapeutic inhibitors.
c. Receptor recognition mechanism of coronaviruses
Middle East respiratory syndrome (MERS) outbreaks have been repeatedly reported since 2012 in the Arabian Peninsula and then in South Korea in 2015. From a structural perspective, Prof. Shi firstly was involved in elucidation of the receptor-recognition mechanisms of the resulting novel coronavirus (MERS-CoV) (Nature, 2013). Recently, his team collaborated with other teams to reveal that the structural features of full-length spike (S) protein ectodomain of MERS-CoV and SARS-CoV, indicating a dynamic process of S protein binding to the receptors (Nature Communications, 2017).
d. Structural biology of ZIKV proteins
The ZIKV nonstructural protein 1 (NS1) plays important roles in viral replication, pathogenesis, and immune evasion. Prof. Shi solved the C-terminal region of ZIKV NS1 protein and showed that the region contains a differential electrostatic potential in the host-interaction interface compared with other analogous flavivirus proteins (Nature Structural & Molecular Biology, 2016). He then reported the crystal structure of the full-length NS1 protein, and found that an extended membrane association interface contributed by the hydrophobic “spike” of a long intertwined loop, providing important information for ZIKV pathogenesis and development of diagnostic tools (EMBO Journal, 2016 cover story). Recently, he solved the high-resolution structures of nonstructural protein 5 (NS5), which is a good target for antiviral drugs, and pointed out the conserved drug binding site in ZIKV NS5 protein compared with other flavivirus NS5 protein (EMBO Journal, 2017). Finally, he and his colleague have summarized the achievements on structural biology of ZIKV and the future challenges and opportunities in this field (Trends in Biochemical Sciences, 2017).
Director for Department of Cancer Epidemiology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China
Evoluation theroy and Frontier technology analysis
Chief of Shanghai Medical Equipment management Quality control Center, Shanghai 6th people’s hospital
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Managing Partner,Shanghai Office
Epidemiological considerations associated with development and application of vaccine
professor / Deputy Director General, Institutes of Biomedical Sciences, Fudan University / National Engineering Laboratory for Therapeutic Vaccines
Xuan-Yi Wang, MD, PhD
Research scientist, Institutes of Biomedical Sciences, and
Professor, Key Laboratory of Medical Molecular Virology of MoE/MoH
Fudan University, China
Deputy director, National Engineering Laboratory for Therapeutic Vaccines
Dr. Wang is a seasoned scientist with an extensive experience in infectious diseases in China. He combines academic knowledge of epidemiology with the crucial understanding of healthcare systems and infrastructure in the remote area of China. Dr. Wang started his career in China where he distinguished himself through his work on hepatitis. He conducted several outstanding studies on hepatitis control. This was followed by a series of successful projects focussing on enteric diseases. He received his Ph.D. from the Department of Epidemiology, School of Public Health, Fudan University, and conducted postdoctoral studies at the Key Lab of Medical Molecular Virology, Shanghai Medical College, Fudan University where he started to apply molecular techniques to the study of viral hepatitis. He joined the International Vaccine Institute as an associated research scientist in 2003. During his work in Seoul, Dr. Wang focused on the studies of enteric infectious disease, such as rotavirus, S.typhi, S.paratyphi, and cholera, interacted with a large multidisciplinary team which included social scientists (behavioural sciences and economics) and statisticians in Southeast Asian and Africa countries.
In 2007, Dr. Wang moved back to Fudan University. His research team studies viral hepatitis and enteric infectious diseases with a strong emphasis on epidemiology and vaccinology. He has involved in the development and implementation of vaccines for hepatitis A, B and E, rotavirus, EV71 in China. Currently, he is responsible for the evaluation for the efficacy of therapeutic hepatitis B vaccine.
Dr. Wang serves as Associate Editor of Human Vaccines & Immunotherapeutics, and Editorial Board Member for Chinese Journal of Vaccines & Immunization, chinese Journal of Microbiology & Immunology, International Journal of Epidemiology & Infectious Disease, and Emerging Microbes & Infections, and ad hoc referee for 8 international journals, including World Health Organization Bulletin, Vaccine, and Human Vaccines & Immunotherapeutics. He became review experts for new vaccine registration at the Center for Drug Evaluation, China Food and Drug Administration in 2009, and member of 1st National Advisory Committee on Immunization Program (NAIC) in 2017. Currently, he serves the member of the Vaccine Professional Committee, Chinese Association of Pharmaceutical Biotechnology, and member of Expert Committee, National Vaccine Industry Technology Innovation Strategic Alliance.
VP Corporate Development and Technical Operation, Sunshine Guojian
Preious Head of Manfuacturing at 3SBIO Shenyang site, graduated in Biochemical Engineering from Dartmouth, and served at four US companies on antibody manufacturing.
Vice General Manager, Director of Process Development, Obio Technology（Shanghai）Corp.,Ltd.